Zymeworks (ZYME) said Monday that new preclinical data for its experimental respiratory inflammation drug ZW1528 has shown positive results.
The drug targets two proteins involved in inflammation and blocks their signals to reduce immune responses, the company said.
In lab studies, ZW1528 worked well at stopping inflammation in immune cells taken from chronic obstructive pulmonary disease patients and also showed strong results in animal tests involving lung inflammation caused by dust mites, it added.
The drug remained stable at high concentrations, supporting the option of administering it through subcutaneous injection, according to the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.